Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 10 Oct 16

Research and Markets has announced the addition of the "GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC - Pipeline Review, H2 2016" report to their offering.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

The GTPase KRas pipeline target constitutes close to 17 molecules, out of which approximately 12 molecules are developed by Companies and the remaining by Universities/Institutes. The molecules developed by Companies in Preclinical and Discovery stages are 2 and 10, respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Our latest report GTPase KRas - Pipeline Review, H2 2016, outlays comprehensive information on targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in GTPase KRas targeted therapeutics development, and features dormant and discontinued projects and the latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. GTPase KRas Overview
  3. Therapeutics Development
  4. Pipeline Products for GTPase KRas - Overview
  5. Pipeline Products for GTPase KRas - Comparative Analysis
  6. GTPase KRas - Therapeutics under Development by Companies
  7. GTPase KRas - Therapeutics under Investigation by Universities/Institutes
  8. GTPase KRas Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. GTPase KRas - Products under Development by Companies
  13. GTPase KRas - Products under Investigation by Universities/Institutes
  14. GTPase KRas - Companies Involved in Therapeutics Development
  • Aurigene Discovery Technologies Limited
  • Boehringer Ingelheim GmbH
  • Horizon Discovery Group Plc
  • Nimbus Therapeutics LLC
  • Nuevolution AB
  • PeptiDream Inc.
  • Tosk Inc.
  • Warp Drive Bio Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 10/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.